Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

The Lost Sleep Factor

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (5) | Next 10 | Previous | Next
falconer66a Member Profile
 
Followed By 74
Posts 1,393
Boards Moderated 0
Alias Born 01/29/04
160x600 placeholder
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS) GlobeNewswire Inc. - 2/24/2020 7:00:10 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 2/20/2020 4:32:14 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:38:56 PM
PURA ALERT - MACD Cross Pushing $0.039 50 Day MA With $0.35 Analyst TGT Recommendation InvestorsHub NewsWire - 2/10/2020 12:50:46 PM
PURA BUY Recommendation at $0.03 Issued By AmericanBulls InvestorsHub NewsWire - 2/7/2020 10:33:33 AM
Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates GlobeNewswire Inc. - 2/6/2020 7:00:10 AM
Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference GlobeNewswire Inc. - 2/4/2020 7:00:10 AM
Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Developmen... GlobeNewswire Inc. - 2/3/2020 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020 GlobeNewswire Inc. - 1/30/2020 7:00:10 AM
Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Dis... GlobeNewswire Inc. - 1/27/2020 7:00:10 AM
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 6:00:00 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
falconer66a   Sunday, 10/29/17 09:00:01 AM
Re: None
Post # of 238730 
The Lost Sleep Factor

Just heard an NPR broadcast interviewing a sleep expert, who said evidence continues to support lack of sleep, inability to sleep well in middle age as a major cause of ensuing Alzheimer’s. Sound sleep induces waste protein (beta-amyloid, et al.) removal from nerves and neurons.

In relation to Anavex 2-73 (which wasn’t mentioned), the drug’s ability to induce strong, healthful sleep, before any Alzheimer’s symptoms begin, may be a major eventual use for the drug. Universal restoration or induction of good sleep in the Australian Alzheimer's patients in the Phase 1/2 study there is significant.

Here’s the scenario (mine). Anavex 2-73 gets approved to treat mid to mild level Alzheimer’s patients, a result of the big Phase 3 study soon to start. Better than anything on the market, it works for most, either stabilizing at-the-start cognition, or actually improves it.

Of course, families then will be bringing to their doctors older, or even middle-aged family members just starting to lose memory. Physicians recognize these behaviors as those seen at the start of Alzheimer’s, and, for the first time, they have a drug they can prescribe. So they start prescribing Anavex 2-73 at the earliest signs of the disease — with high rates of success.

And, with this, they find those people start to sleep well once again. They don't go on to dementia.

The correlation, connection, even cause of Alzheimer’s with early sleep lose or poor quality becomes well known. Finally (perhaps quickly), physicians then start prescribing the drug as a sleep loss prophylactic, knowing that chronic sleep loss or poor quality sleep is a strong predictor or cause of eventual Alzheimer’s. Get to it early, and results are better (perhaps 100%).

Finally, because it has virtually no side effects of concern, Anavex 2-73 becomes a drug prescribed, even mandated for all middle aged people. Health insurance companies quickly recognize that daily consumption of 50mg of Anavex 2-73 reduces the chances of Alzheimer’s by, say, 75%. Everyone in their health insurance plans is required to take the drug, before any symptoms appear.

Consequently, Alzheimer’s and Parkinson’s and Amyotrophic Lateral Sclerosis cases plummet. Health insurance rates are markedly reduced. People lead longer, more productive (health care insurance paying) lives. Medicare costs plummet. Everyone (except nursing homes) benefits.

Think this to be overly optimistic? Do your own look-up of “Alzheimer’s, poor sleep.”

Then, for now, just for fun, figure out a likely range of corporate revenues if every candidate American popped a Anavex 2-73 pill every day. Presently, there are about 40 million age 50 or older. Add in Europeans and others in developed countries around the world, and the number must approach or exceed 100 million. And for the foreseeable future, that number will grow each year.

Anavex 2-73 has the chance to be the best ever, all-win drug.

[This author advises that his postings should not be used to prompt any AVXL buy or sell decision. Anavex Life Sciences Corp is presently a small, no-revenues, no-product start up pharmaceutical. It may have a great future, as its science is unique and effective. But, of course, never put at risk any non-discretionary funds.]


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (5) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist